全文获取类型
收费全文 | 2366篇 |
免费 | 193篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 72篇 |
妇产科学 | 41篇 |
基础医学 | 324篇 |
口腔科学 | 97篇 |
临床医学 | 202篇 |
内科学 | 612篇 |
皮肤病学 | 62篇 |
神经病学 | 241篇 |
特种医学 | 64篇 |
外科学 | 231篇 |
综合类 | 8篇 |
一般理论 | 1篇 |
预防医学 | 177篇 |
眼科学 | 18篇 |
药学 | 213篇 |
中国医学 | 8篇 |
肿瘤学 | 186篇 |
出版年
2024年 | 3篇 |
2023年 | 30篇 |
2022年 | 55篇 |
2021年 | 128篇 |
2020年 | 61篇 |
2019年 | 85篇 |
2018年 | 87篇 |
2017年 | 72篇 |
2016年 | 86篇 |
2015年 | 95篇 |
2014年 | 119篇 |
2013年 | 120篇 |
2012年 | 203篇 |
2011年 | 195篇 |
2010年 | 107篇 |
2009年 | 83篇 |
2008年 | 157篇 |
2007年 | 156篇 |
2006年 | 146篇 |
2005年 | 135篇 |
2004年 | 123篇 |
2003年 | 112篇 |
2002年 | 89篇 |
2001年 | 10篇 |
2000年 | 8篇 |
1999年 | 9篇 |
1998年 | 12篇 |
1997年 | 14篇 |
1996年 | 12篇 |
1995年 | 7篇 |
1994年 | 9篇 |
1993年 | 5篇 |
1992年 | 2篇 |
1991年 | 6篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 5篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1983年 | 5篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1954年 | 1篇 |
1947年 | 1篇 |
排序方式: 共有2572条查询结果,搜索用时 15 毫秒
141.
142.
Wu YZ Medjane S Chabot S Kubrusly FS Raw I Chignard M Touqui L 《American journal of respiratory and critical care medicine》2003,168(6):692-699
We previously showed that surfactant inhibits the synthesis of type IIA secretory phospholipase A2 (sPLA2-IIA) by alveolar macrophages. These cells have been identified as the main source of this enzyme in an animal model of acute lung injury. The aim of the present study was to identify the surfactant components involved in the inhibition of sPLA2-IIA expression in alveolar macrophages and the signaling pathways that mediate this inhibition. Our results show that various surfactant preparations can inhibit sPLA2-IIA expression in endotoxin-stimulated alveolar macrophages. Both the surfactant protein (SP)-A and the surfactant phospholipid fraction inhibit this expression. The surfactant phospholipid dioleylphosphatidylglycerol (DOPG) abolishes sPLA2-IIA expression, whereas dipalmitoylphosphatidylcholine does not. Chromatographic analysis and confocal microscopy revealed that phosphatidylglycerol was rapidly incorporated and metabolized by alveolar macrophages and that its metabolites accumulate in the cytosol. Nuclear factor-kappaB (NF-kappaB) modulates sPLA2-IIA expression in endotoxin-activated alveolar macrophages, and surfactant preparations, surfactant phospholipid fraction, SP-A, and DOPG indeed suppressed NF-kappaB activation. In summary, our results show that SP-A and DOPG play a role in the surfactant-mediated inhibition of sPLA2-IIA expression in alveolar macrophages and that this inhibition occurs via a downregulation of NF-kappaB activation. 相似文献
143.
Intravascular hemolysis in patients with new-generation prosthetic heart valves: a prospective study 总被引:2,自引:0,他引:2
Mecozzi G Milano AD De Carlo M Sorrentino F Pratali S Nardi C Bortolotti U 《The Journal of thoracic and cardiovascular surgery》2002,123(3):550-556
OBJECTIVE: A prospective clinical study was designed to assess the frequency and severity of intravascular hemolysis in patients with new-generation, normally functioning prosthetic heart valves. METHODS: Hemolysis was evaluated in 172 patients with a mechanical prosthesis (53 CarboMedics and 119 Sorin Bicarbon) and in 106 patients with a bioprosthesis (15 St Jude Medical Toronto, 19 Baxter Perimount, and 72 Medtronic Mosaic) in the aortic position, mitral position, or both. Aortic valve replacement was performed in 206 patients, mitral valve replacement in 59 patients, and double valve replacement in 13 patients. The presence of hemolysis was assessed on the basis of the level of serum lactic dehydrogenase and serum haptoglobin and the presence and amount of reticulocytes and schistocytes in the peripheral blood. Severity of intravascular hemolysis was estimated on the basis of serum lactic dehydrogenase. Clinical, echocardiographic, and hematologic evaluations were performed 1, 6, and 12 months after discharge. RESULTS: None of the 278 patients experienced decompensated anemia, whereas at 12 months, mild subclinical hemolysis was identified in 49 patients, 44 (26%) with a mechanical prosthesis and 5 (5%) with a bioprosthesis (P <.001). At multivariate analysis, independent predictors of the presence of subclinical hemolysis were mitral valve replacement (P <.001), use of a mechanical prosthesis (P =.002), and double valve replacement (P =.02). Frequency of hemolysis in patients with stented aortic bioprostheses was 3%, whereas it was absent in those with stentless valves. Among mechanical valve recipients, double versus single valve replacement (P =.04) and mitral versus aortic valve replacement (P =.05) were correlated with the presence of hemolysis; double valve recipients also showed a more severe degree of hemolysis (P =.03). In patients with a Sorin Bicarbon prosthesis, hemolysis was less frequent (22% vs 34%, P =.09) and severe (P <.001) than in those with a CarboMedics prosthesis. CONCLUSIONS: In normally functioning prosthetic heart valves, subclinical hemolysis is a frequent finding. A low incidence of hemolysis is found in stented biologic prostheses, and it is absent in stentless aortic valves. Modifications of valve design may contribute to minimize the occurrence of hemolysis in mechanical prostheses. 相似文献
144.
145.
Glomerular cell replication and cell loss through apoptosis in experimental diabetes mellitus 总被引:12,自引:0,他引:12
AIM: To evaluate changes in the glomerular cell balance between replication and apoptosis in experimental diabetes mellitus (DM) in relation to morphometric data. METHODS: Adult Sprague-Dowley rats with streptozotocin-induced DM and controls of the same age and strain were sacrificed 4 and 8 weeks and 6 months after disease onset. Cell replication was demonstrated with MIB-5, and apoptosis with the terminal uridine nick end labeling technique. Glomerular size and glomerular cell population were estimated morphologically. RESULTS: Diabetic and control rats showed irrelevant MIB-5 positivity at all time points. Glomerular apoptosis was minimal in rats with 4 and 8 weeks of DM and in controls. Rats with 6 months of DM showed significantly higher glomerular apoptosis values than controls (2.49 +/- 0.25 vs. 0.65 +/- 0.16%; p < 0.001). The mean cell count per glomerular profile was significantly lower in these diabetic rats (64.02 +/- 1.93 vs. 78.27 +/- 0.99; p < 0.001), a change that correlated with that in apoptosis. The glomerular cell density was further decreased in diabetic rats because of the diabetic increase in mean glomerular volume (1.598 vs. 0.927 10(6) microm). CONCLUSIONS: Apoptosis is associated with loss of glomerular cells in rats with long-term, streptozotocin-induced DM and - to a considerably lower degree - in controls of the same age and strain. These changes could be relevant to glomerulosclerosis associated with long-term, streptozotocin-induced DM. 相似文献
146.
alpha-Melanocyte-stimulating hormone protects the allograft in experimental heart transplantation 总被引:7,自引:0,他引:7
Gatti S Colombo G Buffa R Turcatti F Garofalo L Carboni N Ferla L Fassati LR Lipton JM Catania A 《Transplantation》2002,74(12):1678-1684
BACKGROUND: With the increasing need for organ transplantation and the use of "marginal" organs, novel approaches are sought to increase the efficiency and survival of transplanted tissue. We tested the idea that treatment with the anti-inflammatory peptide, alpha-melanocyte-stimulating hormone (alpha-MSH), an endogenous hormone that does not cause marked immunosuppression but does reduce reperfusion injury, may protect allografts and prolong their survival. METHODS: Donor cardiac grafts (Brown Norway) were transplanted heterotopically into the abdomen of recipient (Lewis) rats. Treatments consisted of intraperitoneal injections of Nle DPhe -alpha-MSH (NDP-alpha-MSH) or saline from the time of transplantation until sacrifice or spontaneous rejection. Allografts were removed on day 1, day 4, or at the time of rejection and examined for histopathology and expression of molecules prominent in reperfusion injury, transplant rejection, and apoptosis. RESULTS: NDP-alpha-MSH treatment caused a significant increase in allograft survival and a marked decrease in leukocyte infiltration. Expression of molecules such as endothelin 1, chemokines, and adhesion molecules, which are involved in allograft rejection, was significantly inhibited in NDP-alpha-MSH-treated rats. CONCLUSIONS: The results indicate that protection of the allograft from early injury with alpha-MSH can postpone rejection. Addition of this early protection with the peptide to usual treatment with immunosuppressive agents may, therefore, improve success of organ transplants. 相似文献
147.
148.
Vestergaard P Jørgensen JO Hagen C Hoeck HC Laurberg P Rejnmark L Brixen K Weeke J Andersen M Conceicao FL Nielsen TL Mosekilde L 《Clinical endocrinology》2002,56(2):159-167
OBJECTIVE: The pituitary secretes many hormones of significance to bone turnover and thus skeletal integrity. The aim of this study was to examine fracture risk in patients with pituitary disorders with special reference to GH deficiency and hyperprolactinaemia. DESIGN: Case-control study. MEASUREMENTS: Fracture occurrence. PATIENTS: A self-administered questionnaire was issued to 537 consecutive patients with pituitary disorders excluding Cushing's disease. A total of 426 (79%) returned the questionnaire and 422 of these could be analysed. Each respondent was compared to three age- and gender-matched control respondents to the same questionnaire drawn randomly from the background population. RESULTS: The patients had a mean age of 51.4 +/- 14.8 years. One hundred and eight patients had acromegaly, 86 had prolactinomas, 136 had non-functioning pituitary adenomas (NFPA), 23 had craniopharyngiomas, and 73 had other types of pituitary disorders. For the total group the fracture risk was not elevated either before or after confirmed diagnosis compared to controls. However, among the patients with prolactinomas, the fracture risk was significantly increased before (relative risk, RR = 1.6, 95% CI: 1.1--2.3) but not after diagnosis. In patients with NFPA, fracture risk was borderline significantly elevated following diagnosis (RR = 1.6, 95% CI: 1.0--2.6). Patients with subnormal stimulated peak GH values suggestive of GH deficiency had a significantly higher risk of fractures after diagnosis than patients who had normal stimulated peak GH values (odds ratio, OR = 4.90, 95% CI: 1.10--21.88). CONCLUSIONS: Untreated prolactinomas were associated with a significant increase in fracture risk. Growth hormone deficiency was also associated with a higher fracture risk. 相似文献
149.
Rate of knee cartilage loss after partial meniscectomy 总被引:7,自引:0,他引:7
Cicuttini FM Forbes A Yuanyuan W Rush G Stuckey SL 《The Journal of rheumatology》2002,29(9):1954-1956
OBJECTIVE: Surgical removal of the meniscus of the knee is thought to be a risk factor for later appearance of knee osteoarthritis (OA). We examined whether there is a difference in cartilage loss in those who undergo a partial meniscectomy compared to healthy controls. METHODS: Eight patients who underwent a meniscectomy (5 partial medial, 3 partial lateral) and 13 controls with normal knee radiographs and magnetic resonance imaging (MRI) had an MRI at baseline and at a mean 28.6 +/- 7.6 months followup. Articular cartilage volumes were determined by processing images acquired in the sagittal plane using T1 weighted fat saturation MRI on an independent work station. RESULTS: The mean +/- SD of percentage rates of cartilage loss from baseline volume were 4.1 +/- 2.8% per year for the meniscectomy subjects and -2.3 +/- 3.0% per year for the controls (difference 6.5% per year, 95% CI 3.7-9.3% per year; p < 0.001). After adjustment for age, body mass index, and sex the difference increased slightly to 6.9% per year (95% CI 3.4-10.3%; p = 0.001). CONCLUSION: This study suggests that significant rates of cartilage loss are seen in subjects post partial meniscectomy compared with healthy controls. This may be a useful model in which to examine therapies to prevent OA. 相似文献
150.
Giorgia Mangili M.D. Massimo Franchi M.D. Andrea Mariani M.D. Flavia Zanaboni M.D. Emanuela Rabaiotti M.D. Luigi Frigerio M.D. Pier Francesco Bolis M.D. Augusto Ferrari M.D. 《Gynecologic oncology》1996,61(3):345-348
Intestinal obstruction is a common and distressing clinical complication in ovarian cancer. The aim of our study was to assess vomit control in terminal ovarian cancer patients with inoperable gastrointestinal obstruction, using a symptomatic pharmacological treatment with octreotide which obviates the need for nasogastric tube placement. We studied 13 patients, all of whom had advanced ovarian cancer FIGO stage IIIc. Seven patients were treated in the Gynecology Department of S. Raffaele Hospital, at the University of Milan, and 6 were managed in the University of Varese Hospital. Octreotide was administered at doses starting with 0.3 up to 0.6 mg (mean 0.44 mg) a day by subcutaneous bolus or continuous infusion. Octreotide controlled vomiting in all cases to grade 0 on the WHO emesis scale. Complete relief of symptoms was achieved within 3.07 days (range 1–6 days). Vomiting stopped within 2–3 days of starting treatment in most patients. In 8 patients with a nasogastric tube, drainage decreased from 2000 to under 100 ml/day after the start of octreotide treatment. No side effects were reported. All patients died with minimal distress or pain. 相似文献